Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
Date:10/30/2008

been $104.3 million. This represents a current year increase of $106.9 million or 102%. Of this increase, $98.4 million is the result of acquisitions and the remainder is due to increased sales and gross profit, partially offset by higher R&D and selling, general and administrative ("SG&A") expense.

Excluding the newly acquired entities, R&D expense increased by $8.8 million or 26% to $42.4 million primarily as a result of increased Abbreviated New Drug Application (ANDA) submissions and payments made under product development agreements. SG&A expense for the three months ended Sept. 30, 2008, also excluding newly acquired entities, increased by $25.6 million or 26% to $122.6 million. The majority of this increase was realized by Corporate and Other, and is the result of costs associated with the integration of the former Merck Generics business, as well as higher payroll and related costs principally attributable to the build-up of additional corporate infrastructure as a direct result of the acquisition.

Interest expense for the current quarter totaled $87.6 million compared to $23.1 million for the three months ended Sept. 30, 2007. The increase is due to the additional debt incurred to finance the acquisition of the former Merck Generics business.

Other income, net, was $5.8 million for the three months ended Sept. 30, 2008, compared to $166.8 million in the same prior year period. The comparable quarter for 2007 included a $142.5 million non-cash mark to market unrealized gain on a deal-contingent foreign currency option contract that was entered into for the then pending acquisition of the former Merck Generics business. Excluding this unrealized gain, the decrease in other income, net, in the current year is due primarily to lower interest and dividend income as a result of lower cash and available for sale securities.

EBITDA for the quarter ended Sept. 30, 2008, which is defined as net income (loss) (excluding minority interest a
'/>"/>

SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
2. Mylan to Host Investor Day on October 3, 2007
3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
4. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
5. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
6. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
7. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
8. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets
9. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
10. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)...  Turing Pharmaceuticals AG announced that life sciences executive ... MSc,  has joined the company as president of ... holds a medical degree as well as a ... accomplishments in the pharmaceutical industry, and extensive clinical ... played a leadership role in numerous programs for ...
(Date:6/1/2015)... and RARITAN, N.J. , ... LLC (Janssen) announced data from the Phase 3 ... in progression-free survival (PFS) with trabectedin (YONDELIS ® ... liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated with ... regimen. SAR3007 is the largest randomized Phase 3 ...
(Date:6/1/2015)... 1, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") ... 2015.  Biorem,s complete 2015 first quarter financial statements and MD&A have ... ended March 31,(in CDN$,000 except per share data) , ... , 1,974 Gross profit , 1,531 , ... (loss) , 528 , (531) Basic earnings (loss) ...
(Date:6/1/2015)... , June 1, 2015  The Val Skinner ... national innovative science curriculum for high school students focused ... 16 th annual LIFE Event (LPGA Pros in ... Ridge Country Club in West Caldwell, N.J. ... LPGA,s biggest stars raised more than $500,000 on Monday, ...
Breaking Biology Technology:Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6Biorem Reports Increased Revenues and Earnings for First Quarter 2Biorem Reports Increased Revenues and Earnings for First Quarter 3Val Skinner Foundation Announces Partnership With Discovery Education 2
... England, April 21 Paul Capital,Healthcare and Vernalis ... a financing agreement relating to frovatriptan, Vernalis, product,for ... will receive,approximately euro 18.4 million in cash from ... will receive approximately 90 per cent,of Menarini,s payments ...
... MIT Lincoln Laboratory have developed a powerful sensor ... and smallpox in less than three minutes. , ... for THreatening Environmental Releases), represents a significant advance ... Lincoln Lab,s Biosensor and Molecular Technologies Group. Current ...
... b3c newswire /   -  DuoCort AB announced ... Optimized Care for Adrenal Insufficiency – at the 10th ... Congress Centrum in Berlin.  The symposium will be held ... delegates attending ECE 2008 are invited to the symposium. ...
Cached Biology Technology:Vernalis and Paul Capital Healthcare Sign euro 18.4 Million Financing Agreement 2Vernalis and Paul Capital Healthcare Sign euro 18.4 Million Financing Agreement 3MIT's PANTHER sensor quickly detects pathogens 2DuoCort Hosts Adrenal Insufficiency Symposium at the 10th European Congress of Endocrinology in Berlin 2
(Date:5/7/2015)... 7, 2015 Fingerprint Cards ... and FPC1035, FPC,s smallest touch fingerprint sensors to ... considered for integration on the backside of the ... increased possibilities to integrate touch fingerprint sensors in ... improves possibilities for module manufacturers to customize the ...
(Date:4/27/2015)... Apr. 27, 2015 Profile Solutions, Inc. (OTC: ... security systems is pleased to announce that Dr ... consultant and member of its scientific advisory board. ... as a thought leader in technology-enhanced learning models. He ... and has published studies and books focused on online ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... the cells of blood vessels running through ovarian tumors. ... diagnosis and treatment for this disease. , The team ... Pennsylvania, and universities in Greece and Italy, used a ... ovarian tumors and four normal ovarian tissue samples. From ...
... markedly in their response to sleep deprivation, but the ... identify. Researchers have now found that a genetic difference ... particularly sensitive to the effects of sleep deprivation. The ... at the University of Surrey's Sleep Research Center, appear ...
... machine of their design, Duke University Medical Center researchers ... improve the ability of physicians to repair damaged joints ... experiments are successful, the scaffold could be used in ... Moutos, a graduate student in the Orthopedic Bioengineering Laboratory ...
Cached Biology News:Researchers identify ovarian cancer biomarkers 2Individual differences in a clock gene predict decline of performance during sleep deprivation 2Woven scaffolds could improve cartilage repair 2
... system is used for conventional PCR and ... MyCycler personal thermal cycler, which features a ... ml tubes or plates, programmable time, temperature, ... block modes of temperature control. The system ...
... Ciphergen's ProteinChip arrays have been ... from biological samples. A variety of ... of proteins according to their unique ... different spots, allowing side-by-side sample comparison, ...
The Freeze 'N Squeeze DNA gel extraction kit uses a quick freeze-and-thaw cycle and centrifugation to draw 50-23,000 bp DNA out of agarose gel slices. The kit includes materials for 100 preps....
The Econo gradient pump rack is a preassembled rack that is used to hold the components of the Econo gradient pump kits....
Biology Products: